Becton, Dickinson and Company (BDX)
(Delayed Data from NYSE)
$233.25 USD
-3.09 (-1.31%)
Updated Sep 5, 2024 04:00 PM ET
After-Market: $233.15 -0.10 (-0.04%) 7:50 PM ET
3-Hold of 5 3
B Value B Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$233.25 USD
-3.09 (-1.31%)
Updated Sep 5, 2024 04:00 PM ET
After-Market: $233.15 -0.10 (-0.04%) 7:50 PM ET
3-Hold of 5 3
B Value B Growth D Momentum B VGM
Zacks News
Based in Franklin Lakes, NJ, Becton, Dickinson and Company (BDX) commonly known as BD, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. In fiscal 2019, BD’s revenues increased 8.2% to $17.29 billion. Earlier, BD’s operations consisted of three business segments: BD Medical, BD Diagnostics and BD Biosciences. However, the company’s organizational structure was realigned to form two principal business segments: BD Medical, BD Life Sciences and BD Interventional.
Here's Why You Should Retain BD (BDX) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about BD (BDX) owing to its slew of regulatory approvals and strategic deals.
BD's (BDX) Buyout of Venclose to Improve Patient Outcome
by Zacks Equity Research
BD's (BDX) acquisition of Venclose is expected to deliver a patient-centric approach to care.
The Zacks Analyst Blog Highlights: Accenture, Raytheon, Becton, Dickinson and Co, Boeing and Gilead Sciences
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Accenture, Raytheon, Becton, Dickinson and Co, Boeing and Gilead Sciences
Top Analyst Reports for Accenture, Raytheon & Becton, Dickinson
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Accenture plc (ACN), Raytheon Technologies Corporation (RTX), and Becton, Dickinson, and Company (BDX).
BD (BDX) Beats on Q4 Earnings and Revenues, FY22 View Issued
by Zacks Equity Research
Each of BD's (BDX) core units witnesses strong revenue growth in the fiscal fourth quarter, driving up the overall top line.
Becton Dickinson (BDX) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Becton Dickinson (BDX) delivered earnings and revenue surprises of 6.58% and 4.73%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Medical Products' Nov 4 Earnings Roster: BDX, ZBH & More
by Trina Mukherjee
The Medical Product companies' Q3 results are likely to reflect huge adoption of their COVID-related support products. Let's see how BDX, ZBH, ABC and XRAY are poised ahead of their earnings releases.
Is a Surprise Coming for BD (BDX) This Earnings Season?
by Zacks Equity Research
BD (BDX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Clover Health (CLOV) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
Clover Health's (CLOV) third-quarter results are likely to benefit from Direct Contracting and strategic partnerships.
Zimmer Biomet (ZBH) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
Strong surgeon registrations of the Signature One surgical planning system for shoulder procedures are likely to have driven Zimmer Biomet's (ZBH) growth in Q3.
Becton Dickinson (BDX) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Becton Dickinson (BDX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BD (BDX) Gears Up for Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Continued strength in BD's (BDX) Life Sciences and Interventional segments is expected to have driven up Q4 sales.
IDEXX (IDXX) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Strong organic recurring revenue growth in CAG diagnostics business and the recent ezyVet buyout are likely to have contributed to growth for IDEXX (IDXX).
What's in Store for Henry Schein (HSIC) in Q3 Earnings?
by Zacks Equity Research
Strengthening demand in the global dental and medical markets along with the recent investments are likely to have contributed to Henry Schein's (HSIC) Q3 performance.
Can Becton Dickinson (BDX) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
Becton Dickinson (BDX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
SmileDirectClub (SDC) Introduces Two New Water Flossers
by Zacks Equity Research
SmileDirectClub (SDC) launched the new Large Tank and Compact Water Flossers, currently available at Shop.SmileDirectClub.com, Amazon, Walmart and Walmart.com.
Zacks.com featured highlights include: Becton, Dickinson and Co, Ternium and AutoNation
by Zacks Equity Research
Zacks.com featured highlights include: Becton, Dickinson and Co, Ternium and AutoNation
QIAGEN's (QGEN) New Manchester Facility to Fortify UK Foothold
by Zacks Equity Research
QIAGEN's (QGEN) new campus is expected to bring the benefits of transformational molecular diagnostics to Manchester and the global healthcare market.
3 Must-Buy Efficient Stocks to Boost Portfolio Returns
by Tirthankar Chakraborty
Becton, Dickinson and Company (BDX), Ternium (TX) & AutoNation (AN) are three must-buy efficient stocks that can enrich your portfolio now.
BDX or MMSI: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
BDX vs. MMSI: Which Stock Is the Better Value Option?
Teladoc (TDOC) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Robust customer uptake and novel innovations are likely to have contributed to growth for Teladoc (TDOC).
Intuitive Surgical (ISRG) Q3 Earnings Match Estimates, Up Y/Y
by Zacks Equity Research
Intuitive Surgical's (ISRG) third-quarter results reflect strong segmental performance.
The Zacks Analyst Blog Highlights: Oracle, Lowe's, Starbucks, Goldman Sachs and Becton, Dickinson and Co
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Oracle, Lowe's, Starbucks, Goldman Sachs and Becton, Dickinson and Co
Top Stock Reports for Oracle, Lowe's & Starbucks
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Oracle Corporation (ORCL), Lowe's Companies, Inc. (LOW), and Starbucks Corporation (SBUX).
Here's Why You Should Invest In Henry Schein (HSIC) Now
by Zacks Equity Research
Investors continue to be optimistic about Henry Schein (HSIC) on its extensive global foothold and raised 2021 earnings guidance.